Categories
October Surprise 2024

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2 …

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction …